Navigation Links
Isolation of Genomic DNA from Saliva Using the Perfect gDNA Blood Mini ,,, Kit

Jennifer Halcome, Laura Pollock, and Michele Nelson Hurst
Eppendorf 5 Prime, Inc. Introduction

It is not convenient in all instances to have blood drawn for gDNA extraction. The Eppendorf Perfect gDNA Blood Mini Kit was used to extract gDNA from saliva with only slight modifications to the protocol. The unique patent-pending trapping technology results in gDNA that is less sheared than the gDNA isolated using the common chaotropic bind-wash-and-elute technology. The gDNA also performs well in PCR as the main downstream application as well as in other downstream applications.

Materials

  • Perfect gDNA Blood Mini Kit
Required but not supplied:
  • Ethanol 95100%; pipette tips; Microcentrifuge; Eppendorf Thermo-mixer, water bath, or heat block at 70C; 15 ml centrifuge tubes.
  • 1x PBS (sufficient amounts are supplied in the kit for blood work, but additional amounts may be needed for saliva applications)
Method

Isolation of gDNA:

  1. Place 1 ml of saliva into a 15 ml centrifuge tube.
  2. Add 4 ml of 1x PBS.
  3. Centrifuge at 1,800 x g for 5 minutes
  4. Decant the supernatant. Add 200 l 1x PBS and re-suspend pellet.
  5. Add 20 l of Proteinase K solution into a 1.5 ml microcentrifuge tube. Transfer the re-suspension from step 4 into this same tube.
  6. Add 350 l Solution G1 to the microcentrifuge tube and mix.
  7. Incubate in Thermomixer at 70C, 900 rpm, for 10 minutes. A water bath may be used with intermittent vortexing of samples if a Thermomixer is not available.
  8. Centrifuge the sample for 3 minutes at 12,00016,000 x g.
  9. Add 200 l Solution G2 to the tube. Vortex vigorously for 5 seconds. Place a spin column in a fresh microcentrifuge tube. Transfer the sample to the spin column assembly by pouring or pipetting. Incubate the sample at room temperature for 1 minute.
  10. Centrifuge the sample for 2 minutes at 12,00016,000 x g. Remove the spin column and decant flow-through. Place the spin column back into the same tube.
  11. Add 600 l Diluted Wash Buffer to the spin column. Centrifuge for 1 minute at 12,00016,000 x g. Remove the spin column and decant flow-through. Place the spin column back into the same tube.
  12. Add 400 l Diluted Wash Buffer to the spin column. Centrifuge for 3 minutes at 12,00016,000 x g. Carefully remove the spin column without splashing Wash Buffer onto the bottom of the column. Place the spin column into a fresh microcentrifuge tube.
  13. Observe the filter membrane to make sure it is dry before proceeding. If the filter looks shiny, spin an additional 1 to 2 minutes before placing the spin column into the fresh microcentrifuge tube.
  14. Add 200 l Elution Buffer to the spin column, making sure that the buffer comes into contact with the spin column filter. Incubate the sample at 70C for 3 minutes. Centrifuge for 1 minute at 12,00016,000 x g to elute gDNA. Store purified gDNA at 4C.
Gel Electrophoresis for Yield:
Determination
5% of each sample was run on a 0.6% agarose gel in 1x TBE. The gel was stained in ethidium bromide. Intensity as well as size of the band was observed.

PCR:
gDNA was isolated from the saliva of three individuals (see protocol). From each individual sample, 50 ng of purified gDNA was used as a template in 30 l PCR reactions. Two different sized targets of the human beta-globin gene were amplified. The following Eppendorf PCR reagents were used with the concentrations or amounts specified in parenthesis:

  • Taq DNA Polymerase (0.05 Units/l)
  • 10x Taq DNA Polymerase Buffer (1x)
  • 25 mM MgCl2 (0.5 mM)
  • dNTP Mix (0.2 mM)
Primers (Integrated DNA Technologies) specific to the human beta-globin gene were used for all reactions at a final concentration of 0.3 M.

536 bp target:
Forward:
5 GCAGCTACACAGCTACCATTCTGC 3
Reverse:
5 GCAGCCTCACCTTCTTTCATGGAGT 3

2 kb target:
Forward:
5 GAAGAGCCAAGGACAGGTAC 3
Reverse:
5 CCTCCAAATCAAGCCTCTAC 3

PCR reactions were performed on the Eppendorf Mastercycler gradient using the following cycling conditions:

536 bp fragment:
94C for 5 minutes; initial denaturation
35 cycles:
94C for 1 minute denaturation
69.6C for 20 seconds annealing
72C for 2 minutes extension
72C for 5 minutes final extension
15C hold

2 kb fragment:
94C for 5 minutes; initial denaturation
35 cycles:
94C for 45 seconds
70C for 20 seconds
72C for 1 minute
72C for 5 minutes final extension
15C hold

Results

Average yields obtained from 1 ml of saliva vary from person to person, but are consistent when triplicate samples are processed for one person (see Fig. 1). In general, the yields are slightly less than the yields of 200 l of whole blood, but extremely high yields have also been observed. All samples perform equally well in PCR with no inhibition of amplification (see Fig.2).

Fig.1: Yields of gDNA isolated from two individuals using both the Perfect gDNA kit and the leading competitors kit gDNA was extracted from the saliva of two individuals in triplicate. 5% of each sample was run on a 0.6% agarose gel.

Top: Lane 1: Lambda Hind III Marker (NEB) Lanes 24: EppendorfIndividual #1 Lanes 57: EppendorfIndividual #2 Bottom: Lane 1: Lambda Hind III Marker (NEB) Lanes 24: CompetitorIndividual #1 Lanes 57: CompetitorIndividual #2 Fig. 2: PCR of gDNA isolated from saliva

Lane 1: GeneRuler Ladder Mix (Fermentas) Lane 2: Eppendorf: 50 ng gDNA template, individual #1; 536 bp fragment Lane 3: Eppendorf: 50 ng gDNA template, individual #1; 2 kb fragment Lane 4: Eppendorf: 50 ng gDNA template, individual #2; 536 bp fragment Lane 5: Eppendorf: 50 ng gDNA template, individual #2; 2 kb fragment Lane 6: Qiagen: 50 ng of gDNA template, individual #1; 536 bp fragment Lane 7: Competitor, 50 ng gDNA template, individual #1; 2 kb fragment Lane 8: Competitor, 50 ng gDNA template, individual #2; 536 bp fragment Lane 9: Competitor, 50 ng gDNA template, individual #2; 2 kb fragment Lane 10: 536 bp fragment no template control Lane 11: 2 kb fragment no template control Discussion

The Perfect gDNA Blood Mini Kit provides a versatile method of isolating gDNA from a variety of starting materials including saliva. The isolated DNA analyzed by gel electrophoresis shows consistent yield within triplicate samples from one individual. The DNA also appears to be significantly higher in molecular weight when isolated using the Perfect gDNA Blood Mini Kit in comparison to the competitor. The DNA in saliva can come from many sources including non-human origins such as bacteria and food particles. Success in amplification of the human beta-globin gene shows the presence of sufficient amounts of human gDNA for use in this downstream application. Overall, the Perfect gDNA Blood Mini Kit provides a fast, effective method for purifying gDNA from saliva.

References

  1. Use of the Polymerase Chain Reaction (PCR) process to amplify nucleic acids is covered by U.S. Patent Numbers 4683105 and 4683202 owned by Roche Molecular and requires a license

'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Fast and Easy Isolation of PCR-Ready Genomic DNA from Whole Blood
2. High-Throughput Isolation of Total RNA
3. Simple Isolation of RNA from Tissue and Cultured Cells
4. Fast Isolation of Total RNA from Small Numbers of Cells
5. Comparison of Growth Techniques and Media for the Purpose of Plasmid Isolation from E. coli Using the Eppendorf Perfectprep Plasmid Mini Kit
6. Isolation of Microorganisms
7. Mouse Tail Genomic DNA Isolation Protocol(1)
8. Genomic DNA Isolation Protocol(1,2,3)
9. Basic Plasmid DNA Isolation Protocol
10. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
11. RNA-free Plasmid DNA Isolation Protocol

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Isolation Genomic DNA from Saliva Using the Perfect gDNA Blood Mini Kit

(Date:11/24/2009)...re-Asia/--ShanghaiBiolaxyannouncedthe,ChineseState...vestigationalnewdrugapplication(IND)foritsoralinsu...totreatdiabetes.ThisIND,approvalallowsBiolaxytoini...sadisordercharacteristicofhighbloodglucoseandpoor,...severemicro-and,macro-vasculardiseases,lossofvisio...
(Date:11/24/2009)...asbeenmetforpatientswithadvanced-stage,orrecurrent...wire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;...panyfocusedonendocrinetherapyandoncology,todayanno...rgetedcytotoxicpeptideconjugate,AEZS-108(formerlyA...lcancer.Inapersonalizedhealthcareapproach,thestudy...
(Date:11/24/2009)...ewswire-FirstCall/--ArenaPharmaceuticals,Inc.(Nasd...dtopresentatthePiperJaffray21stAnnualHealthCareCon...a.m.PacificTime)attheNewYorkPalaceHotelinNewYorkCi...icer,isscheduledtoprovideanoverviewofthecompany,in... ,, Aliveaudiowebcastofthepresentationwillbeava...
(Date:11/24/2009)...m Connects Customers with Partners Validated to Pr...ek Products , Ottawa, ON ...ing provider of products for biological sample col...unced its new global partner program. The program ...partner community and is designed to help partners...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...poration,(Nasdaq: PODD ), the manufacturer and ma..., today announced that Duane DeSisto, Chief Execut... Partners Healthcare,Conference. Mr. DeSisto is sc...:50 p.m. Eastern Time on September 6, 2007 at The ...erence presentation, material information concerni...
...genetics,(Nasdaq: DCGN ) today announced that it ...sson,s presentation at the Thomas Weisel Partners ...ll be delivered at 4:25pm EDT on Wednesday,Septemb...be accessed,through the Investors page on deCODE,s...ested in listening should log on a few minutes in ...
...m,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today ann...Partners 2007 Healthcare Conference will be webcas...rs section of the Company,s,website, http://www.m...i-bin/prnh/19991220/MLNMLOGO ) The presentation ...es,and upcoming milestones. The presentation will ...
Other Biology Technology:Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2
(Date:11/24/2009)..., BATON ROUGE Antarctica has long held secrets o...d until recently, there has been very little infor...eneath miles of ice for millions of years. Now, a ...ing LSU have been funded to the tune of $10 milli...NSF, to get to the bottom of things literally. Th...
(Date:11/24/2009)... This release is available in Spanish . , ...higher levels of inflammatory substances in the bl...ht; as shown by a research project of the Universi...o, a scientist at the School of Pharmacy. , The ... study in relation to the control of body weight a...
(Date:11/23/2009)..., Cambridge, Mass. November 23, 2009 Applied ...ntain lily ( Hosta lancifolia ), a characteristic ...osely packed ripples along the edges. The simple c...n resulting from bending during differential growt..., stretching foam ribbons. , Haiyi Liang, a post...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2It can be predicted the reaction obese patients will have to a diet 2The cause behind the characteristic shape of a long leaf revealed 2iMedX Announces Investment of 2413M From RFE Investment Partners 54175 1iMedX Announces Investment of 2413M From RFE Investment Partners 54175 2Wound Management Technologies Reaches Agreement in Principle for Exclusive Distribution of CellerateRx 28R 29 Products in Italy 54173 1Wound Management Technologies Reaches Agreement in Principle for Exclusive Distribution of CellerateRx 28R 29 Products in Italy 54173 2Wound Management Technologies Reaches Agreement in Principle for Exclusive Distribution of CellerateRx 28R 29 Products in Italy 54173 3Tolerx Announces Amendment to Phase 3 DEFEND Protocol 13495 1Tolerx Announces Amendment to Phase 3 DEFEND Protocol 13495 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 13495 3
...ff a cliff. Another prefers to read a book and wou...es exist is a mystery, but for the first time rese...tion behind risk-seeking behavior. , Scientists a...d that a specific neurodevelopmental gene, called ...d-shaped area of the brain called the amygdala, th...
...al shark skin could help ships sailing smoothly. T... ship hulls is a major cause of increased energy c...ructural design that prevents this so called ,bio-...pplied Sciences, Bremen, Germany, is presenting hi... in a new anti-fouling strategy at the Society for...
...ly needed by 2020 just to maintain consumption lev...he poor and for helping Africa cope with the healt...e HIV and AIDS, the New Partnership for Africa,s D...ers are making an urgent appeal to boost the conti...tion of fisheries to economic growth and food secu...
Other Biology News:Study identifies gene in mice that may control risk-taking behavior in humans 2Study identifies gene in mice that may control risk-taking behavior in humans 3Leptin-signaling Protein Maintains Normal Body Weight And Energy Balance In Mice 2Leptin-signaling Protein Maintains Normal Body Weight And Energy Balance In Mice 3Leptin-signaling Protein Maintains Normal Body Weight And Energy Balance In Mice 4Leptin-signaling Protein Maintains Normal Body Weight And Energy Balance In Mice 5
Murashige and Skoog Basal Medium with Gamborg's Vitamins from Sigma-Aldrich
... hybridization chamber assembly (1 each) Componen...Microarray chamber user guide plastic tweezersCha...leaned and reused. The chamber is designed for use...ll custom oligo microarrays, in conjunction with A...
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
...ynthetic peptide whose sequence corresponds to res...peptide is (amino to carboxy terminus): M(1) - A -... - D - Q - N(18). This peptide may be used for n...yclonal antibody that reacts with this product and...
Biology Products: